次级胆汁酸可改善非酒精性脂肪性肝病中轻度肝纤维化无创识别的风险预测
该研究纳入550例经活检证实为非酒精性脂肪性肝病(NAFLD)的中国成人,采用超高效液相色谱-串联质谱定量38种血清胆汁酸。结果显示,与无纤维化者相比,轻度纤维化(F1期)患者次级胆汁酸水平显著升高;血清胆汁酸联合腰围、舒张压、丙氨酸氨基转移酶或胰岛素抵抗稳态模型评估在识别轻度纤维化方面表现良好,训练集AUROC分别为0.80、0.88、0.75和0.78,测试集分别为0.69、0.80、0.61和0.69。作者结论认为,次级胆汁酸水平在NAFLD中显著升高,尤其在轻度纤维化患者中,血清胆汁酸联合临床/生化标志物识别轻度纤维化的价值值得进一步评估。
要点
- 轻度纤维化(F1期)NAFLD患者次级胆汁酸水平显著高于无纤维化者。
- 血清胆汁酸联合腰围、舒张压、ALT或HOMA-IR识别轻度纤维化训练集AUROC为0.75–0.88。
- 血清胆汁酸联合临床/生化标志物识别显著纤维化(F2-4)表现较差,训练集AUROC为0.71–0.75。
核心结论
- 次级胆汁酸水平在NAFLD中显著升高,尤其在轻度纤维化患者中。
- 血清胆汁酸联合临床/生化标志物识别轻度纤维化的价值值得进一步评估。
研究设计与样本
- 研究纳入550例经活检证实为NAFLD且纤维化程度不同的中国成人。
- 采用超高效液相色谱-串联质谱定量38种血清胆汁酸。
主要发现
- 与无纤维化者相比,轻度纤维化(F1期)患者次级胆汁酸水平显著升高,舒张压、丙氨酸氨基转移酶、体重指数和腰围亦升高。
- 血清胆汁酸联合腰围、舒张压、丙氨酸氨基转移酶或胰岛素抵抗稳态模型评估识别轻度纤维化,在男性和女性、肥胖和非肥胖者中均表现良好,训练集(n=385)AUROC分别为0.80、0.88、0.75和0.78,测试集(n=165)分别为0.69、0.80、0.61和0.69。
- 血清胆汁酸联合临床/生化标志物识别显著纤维化(F2-4)表现较差,在女性和非肥胖者中训练集AUROC分别为0.75和0.71,验证集分别为0.65和0.66。
- 上述AUROC高于纤维化-4指数、NAFLD纤维化评分和Hepamet纤维化评分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dysregulated bile acid (BA) metabolism has been linked to steatosis, inflammation, and fibrosis in nonalcoholic fatty liver disease (NAFLD). AIM: To determine whether circulating BA levels accurately stage liver fibrosis in NAFLD. METHODS: We recruited 550 Chinese adults with biopsy-proven NAFLD and varying levels of fibrosis. Ultra-performance liquid chromatography coupled with tandem mass spectrometry was performed to quantify 38 serum BAs. RESULTS: Compared to those without fibrosis, patients with mild fibrosis (stage F1) had significantly higher levels of secondary BAs, and increased diastolic blood pressure (DBP), alanine aminotransferase (ALT), body mass index, and waist circumstance (WC). The combination of serum BAs with WC, DBP, ALT, or Homeostatic Model Assessment for Insulin Resistance performed well in identifying mild fibrosis, in men and women, and in those with/without obesity, with AUROCs 0.80, 0.88, 0.75 and 0.78 in the training set (n = 385), and 0.69, 0.80, 0.61 and 0.69 in the testing set (n = 165), respectively. In comparison, the combination of BAs and clinical/biochemical biomarkers performed less well in identifying significant fibrosis (F2-4). In women and in non-obese subjects, AUROCs were 0.75 and 0.71 in the training set, 0.65 and 0.66 in the validation set, respectively. However, these AUROCs were higher than those observed for the fibrosis-4 index, NAFLD fibrosis score, and Hepamet fibrosis score. CONCLUSIONS: Secondary BA levels were significantly increased in NAFLD, especially in those with mild fibrosis. The combination of serum BAs and clinical/biochemical biomarkers for identifying mild fibrosis merits further assessment.
引用
- Liu AN, Xu CF, Liu YR, et al. Secondary bile acids improve risk prediction for non-invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2023. PMID: 36670060. doi:10.1111/apt.17362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。